Group 1 - The National Healthcare Security Administration (NHSA) has introduced a "green channel" for medical insurance coding for innovative medical products such as brain-computer interfaces (BCIs) [1] - The NHSA will expedite the coding process for products that have obtained medical device registration certificates and will also support products that have not yet received certification by allowing submission of technical requirements and clinical evaluation materials [1] - The aim of this initiative is to optimize the classification system for medical consumables under insurance, ensuring it adapts to industry developments and promotes the rapid clinical use of innovative medical products [1] Group 2 - There has been a significant increase in policy support for the brain-computer interface market this year, with the establishment of a comprehensive terminology system for BCIs set to be implemented in January 2026 [2] - The NHSA has introduced independent billing items for BCI technologies, laying the groundwork for future commercialization and clinical application [2] - By 2027, key breakthroughs in BCI technology are expected, with the establishment of advanced technical, industrial, and standard systems, and the application of BCI products across various sectors [2] Group 3 - Major companies are entering the commercialization phase, with the approval of China's first invasive BCI medical device by Nanjing Shanhai Medical Technology Co., Ltd. [3] - Companies like Sainuo Medical and Xiangyu Medical are leveraging their expertise to develop minimally invasive BCI solutions and rehabilitation devices for stroke patients [3] - Sanbo Neuroscience has successfully implanted invasive BCI devices in patients with ALS, enabling them to control robotic arms through thought [3]

三博脑科（301293.SZ）9月24日在投资者互动平台表示，公司脑机接口还处于实验性开展和实验室验证 阶段，距离成熟应用还有一系列验证过程。目前不会对公司产生较大影响。 （记者 谭玉涵） 每经AI快讯，有投资者在投资者互动平台提问：脑机接口纳入医保，会对贵公司产生什么影响？ ...

Core Viewpoint - Sanbo Brain Science experienced a decline of 1.39% in stock price on September 23, with a trading volume of 525 million yuan, indicating potential volatility in the stock market performance [1]. Financing Summary - On September 23, Sanbo Brain Science had a financing buy-in amount of 60.30 million yuan and a financing repayment of 63.94 million yuan, resulting in a net financing outflow of 3.64 million yuan [1]. - As of September 23, the total financing and securities lending balance for Sanbo Brain Science was 639 million yuan, with the financing balance accounting for 6.89% of the circulating market value, indicating a high level of financing activity [1]. - The company had a securities lending repayment of 1,300 shares and a securities lending sell-out of 12,700 shares, with a sell-out amount of 730,100 yuan, reflecting significant trading activity in the securities lending market [1]. Company Performance - As of June 30, the number of shareholders for Sanbo Brain Science reached 43,200, an increase of 14.69% compared to the previous period, while the average circulating shares per person decreased by 12.81% to 3,725 shares [2]. - For the first half of 2025, Sanbo Brain Science reported an operating income of 827 million yuan, representing a year-on-year growth of 17.54%, and a net profit attributable to shareholders of 69.70 million yuan, up 4.60% year-on-year [2]. Dividend and Shareholding Structure - Since its A-share listing, Sanbo Brain Science has distributed a total of 45.10 million yuan in dividends [3]. - As of June 30, 2025, the second-largest circulating shareholder was Huabao Zhongzheng Medical ETF, holding 4.81 million shares as a new shareholder, while the Southern Zhongzheng 1000 ETF increased its holdings by 249,800 shares to 1.33 million shares [3].

Market Overview - The Shanghai Composite Index closed at 3821.83 points, with a decline of 0.18% [1] - The total trading volume of A-shares reached 25,184.71 billion yuan [1] Technical Analysis - A total of 171 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.60 yuan, 10-day MA at 23.25 yuan, a difference of -2.80% [1] - Xiangyu Medical: 5-day MA at 54.48 yuan, 10-day MA at 55.33 yuan, a difference of -1.54% [1] - Northern Long Dragon: 5-day MA at 122.21 yuan, 10-day MA at 123.92 yuan, a difference of -1.38% [1] Stock Performance - Key stocks with notable declines include: - Innovation Medical: down 2.97% with a turnover rate of 16.99% [1] - Xiangyu Medical: down 5.95% with a turnover rate of 2.14% [1] - Northern Long Dragon: down 2.23% with a turnover rate of 20.67% [1] - Other stocks with significant declines include: - Aorui: down 5.25% [1] - Changbai Mountain: down 7.15% [1] - Hengbao Shares: down 6.73% [1]

Core Viewpoint - The A-share market is experiencing a downward trend, with a notable number of stocks showing a death cross between the 5-day and 10-day moving averages, indicating potential bearish signals for investors [1][2]. Group 1: Market Overview - As of 14:01, the Shanghai Composite Index is at 3791.74 points, with a decline of 0.96% [1]. - The total trading volume of A-shares today is 20,627.24 billion yuan [1]. Group 2: Stocks with Death Cross - A total of 211 A-shares have seen their 5-day moving averages cross below the 10-day moving averages [1]. - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical (002173) with a distance of -2.88% [1]. - Jiayun Technology (300242) with a distance of -1.60% [1]. - Xiangyu Medical (688626) with a distance of -1.58% [1]. Group 3: Performance of Specific Stocks - Innovation Medical (002173) is down 3.90% with a trading turnover rate of 15.58% [1]. - Jiayun Technology (300242) has decreased by 4.01% with a turnover rate of 2.40% [1]. - Xiangyu Medical (688626) has dropped 6.38% with a turnover rate of 1.71% [1]. - Other notable declines include: - Beifang Chuanglong (301357) down 4.10% [1]. - Shandong Mining Machinery (002526) down 4.68% [1]. - Kexin Information (300730) down 5.54% [1].

Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]

Core Points - The National Medical Products Administration has approved a new industry standard for medical devices using brain-computer interface (BCI) technology, which will take effect on January 1, 2026, addressing long-standing issues of terminology confusion in the field [1] - A series of supportive policies have been introduced in 2023 to facilitate the application of BCI technology in healthcare, including pricing guidelines for invasive and non-invasive BCI services [2][3] - The market for BCI applications in healthcare is projected to reach $40 billion by 2030, with significant potential in serious medical applications and consumer healthcare [4] Policy Developments - In March 2023, the National Healthcare Security Administration issued guidelines for pricing BCI-related medical services, establishing clear pricing categories for invasive and non-invasive procedures [2] - Zhejiang Province has implemented specific pricing for BCI services, with costs set at 6,580 yuan for invasive implantation, 3,150 yuan for removal, and 960 yuan for non-invasive adaptation [2] - In August 2023, Zhejiang Province announced that non-invasive BCI adaptation fees would be included in basic medical insurance, reducing the out-of-pocket cost for patients to 10% [2] Industry Trends - The clarity in pricing is expected to promote standardized applications of BCI technology in healthcare, reducing competition chaos and attracting more investment [3] - Companies are increasingly investing in the "BCI + healthcare" sector, with notable advancements in practical applications, such as the launch of the first domestic BCI-assisted rehabilitation system for upper limb function [5] - Innovative companies like Zhejiang Qiangnao Technology are emerging as key players in the industry, focusing on non-invasive BCI technologies and developing smart prosthetic products [5] Future Outlook - Experts predict that ongoing research will lead to significant improvements in BCI technology, expanding its applications beyond current disease treatments to a broader range of medical fields [6] - The convergence of favorable policies, standards, capital, and technology is seen as a catalyst for the BCI medical application sector, with early movers likely to gain a competitive edge [6]

Group 1 - The company, Sanbo Brain Science, announced the establishment of a new investment fund to enhance its industry chain and expand its business scale [2] - The fund aims to improve the company's medical service technology level and core competitiveness by leveraging the expertise of professional investment institutions [2] - The fund, named Shanghai Delian Bojian Venture Capital Partnership, has been officially registered with the Asset Management Association of China [2]

证券代码：301293 证券简称：三博脑科 公告编号：2025-040 三博脑科医院管理集团股份有限公司 关于持股 5%以上股东减持股份变动比例触及 1%及 5%整数倍暨 简式权益变动报告书的提示性公告 公司股东 TBP 3Doctors (HK) Limited 保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、本次权益变动前，TBP 3Doctors (HK) Limited（以下简称"TBP""信息披 露义务人"）持有公司股份 31,205,425 股，占公司总股本的 15.14922%，占剔除 公司回购专用账户股份数量后总股本的 15.37290%；本次权益变动后，TBP 持有 公司股份 30,898,025 股，占公司总股本的比例为 14.99999%，占剔除公司回购专 用账户股份数量后总股本的 15.22147%。本次权益变动后，TBP 仍为持有公司 5%以上股份的股东。 2、本次权益变动不触及要约收购。 3、本次权益变动不涉及公司控股股东及实际控制人，不会导致公司控股股 东、实际 ...

三博脑科医院管理集团股份有限公司 简式权益变动报告书 信息披露义务人：TBP 3Doctors (HK) Limited 注册地址：Room 2001-2004, 20/F, Agricultural Bank of China Tower, 50 Connaught Road Central, Central, Hong Kong （香港中环干诺道中50号中国农业 银行大厦20楼2001-2004室） 通讯地址：Room 2001-2004, 20/F, Agricultural Bank of China Tower, 50 Connaught Road Central, Central, Hong Kong （香港中环干诺道中50号中国农业 银行大厦20楼2001-2004室） 股份变动性质：股份减少 简式权益变动报告书签署日期：2025年9月17日 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露了信息披露义务人所持有、控制的在上市公司中拥有权益的股 份变动情况。截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人 没有通过任何其他方式增加或减少其在上市公司 ...